PATENT CLAIM ANALYSIS

Application Number: 16016199
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
Specific Cortistatin derivatives with advantageous properties for in vivo administration to a host, including a human, in need thereof are provided. These novel species have advantageous pharmacokinetics, low toxicity, low to moderate hERG activity, and/or other pharmacological properties which make them stand out among the class of Cortistatins as superior candidates for human administration.

Claim (Index 11):
A method for the treatment of a host with a disorder mediated by CDK8 and/or CDK19 comprising administering to the host an effective amount of a compound selected from or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 94.0
- Lexical Diversity: 1.29787
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15807301', '15981575', '15192629', '15764988', '15374966']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7841391741280034
- 35 USC 102 Novelty (BERT): 0.5391603910463058
- Combined Prediction Score: 0.7596412958198336
- Mean Citation Score: 314.419242
- Max Citation Score: 361.81342
- Similarity Product: 225.21537621239665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test